← Back to Clinical Trials
Recruiting NCT06203314

NCT06203314 Epstein-Barr Virus and Cancer Risks

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06203314
Status Recruiting
Phase
Sponsor Sun Yat-sen University
Condition Cancer
Study Type OBSERVATIONAL
Enrollment 100,000 participants
Start Date 2008-08-01
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 69 Years
Study Type OBSERVATIONAL
Interventions
Diagnostic test: EBV antibody tests

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100,000 participants in total. It began in 2008-08-01 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this prospective cohort study is to investigate the associations between Epstein-Barr Virus (EBV) antibody levels and the risk of overall and site-specific cancer types in Southern China. The main questions it aims to answer are: Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?

Eligibility Criteria

Inclusion Criteria: * Subject residents in Zhongshan or Wuzhou City; * Subject has no medical record of prevalent cancer; * Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study\'s follow-up procedures. Exclusion Criteria: * Subject has heavy cardiovascular, liver, or kidney disease; * Subject has prevalent cancer.

Contact & Investigator

Central Contact

Wei-Hua Jia

✉ jiawh@sysucc.org.cn

📞 86+020-87342327

Frequently Asked Questions

Who can join the NCT06203314 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 69 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06203314 currently recruiting?

Yes, NCT06203314 is actively recruiting participants. Contact the research team at jiawh@sysucc.org.cn for enrollment information.

Where is the NCT06203314 trial being conducted?

This trial is being conducted at Zhongshan, China, Wuzhou, China.

Who is sponsoring the NCT06203314 clinical trial?

NCT06203314 is sponsored by Sun Yat-sen University. The trial plans to enroll 100,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology